Gerasimos Konidaris

Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%

Andreas Kuznik, Caitlin Smare, Chieh-I Chen et al. · Value in Health · 2021 · 32 citations

Pharmacy, Oncology, Pharmacoeconomics +17

Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting

Melanie J. Davies, Divina Glah, Barrie Chubb et al. · PharmacoEconomics · 2016 · 31 citations

Pharmacy, Endocrinology, Pharmacoeconomics +13

Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis

Gerasimos Konidaris, E. Paul, Andreas Kuznik et al. · Value in Health · 2021 · 31 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

Mahmut Gümüş, C. Chen, Cristina Ivanescu et al. · Cancer · 2022 · 20 citations · Full text

Medicine, Oncology, Pharmacology +16

Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3

Tamta Makharadze, Ruben G.W. Quek, Tamar Melkadze et al. · Cancer · 2023 · 16 citations · Full text

Medicine, Oncology, Pharmacology +15